Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
The Lancet. Oncology|December 8, 2016
Neurological sequelae of cancer immunotherapies and targeted therapiesWolfgang Wick, Anne Hertenstein, Michael PlattenNeuro-Oncology|October 14, 2015
Current status and future directions of anti-angiogenic therapy for gliomasWolfgang Wick, Michael Platten, Antje Wick, et al.Journal of Neuro-Oncology|July 17, 2016
Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastomaAnne Hertenstein, Thomas Hielscher, Oliver Menn, et al.Biochemical Pharmacology|June 28, 2011
Suppression of human CD4+ T cell activation by 3,4-dimethoxycinnamonyl-anthranilic acid (tranilast) is mediated by CXCL9 and CXCL10Anne Hertenstein, Theresa Schumacher, Ulrike Litzenburger, et al.Neuro-Oncology|June 15, 2016
Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastomaSina Burth, Philipp Kickingereder, Oliver Eidel, et al.Oncotarget|July 23, 2016
Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapyDieter Lemke, Hans-Werner Pledl, Markus Zorn, et al.Oncotarget|February 17, 2015
Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastomaTobias Kessler, Felix Sahm, Jonas Blaes, et al.Neuro-Oncology|October 11, 2017
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylationTobias Kessler, Felix Sahm, Ahmed Sadik, et al.Oncotarget|November 24, 2016
Prognostic relevance of miRNA-155 methylation in anaplastic gliomaMaximilian Georg Schliesser, Rainer Claus, Thomas Hielscher, et al.Pageof 1